FDA Approves Vibativ for Bacterial Pneumonia
FDA Approves Vibativ for Hospitalized Patients with Bacterial Pneumonia (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 24, 2013 Category: Journals (General) Source Type: news
Vibativ For Bacterial Pneumonia Approved By FDA
Vibativ (telavancin) has been approved by the FDA to treat HABP/VABP (hospital-acquired ventilator-associated bacterial pneumonia) caused by Staphylococcus aureus. The FDA (Food and Drug Administration) added that telavancin should only be used when other treatments are not appropriate. Telavancin is a bactericidal lipoglycopeptide for use in MRSA (Methicillin-resistant Staphylococcus aureus) or other Gram-positive infections. It is a semi-synthetic derivative of vancomycin. The FDA approved telavancin in September 2009 for complicated skin and skin structure infections... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 22, 2013 Category: Consumer Health News Tags: MRSA / Drug Resistance Source Type: news
FDA Approves Vibativ (Telavancin) For Bacterial Pneumonia
Vibativ (telavancin) has been approved by the FDA to treat HABP/VABP (hospital-acquired ventilator-associated bacterial pneumonia) caused by Staphylococcus aureus. The FDA (Food and Drug Administration) added that telavancin should only be used when other treatments are not appropriate. Telavancin is a bactericidal lipoglycopeptide for use in MRSA (Methicillin-resistant Staphylococcus aureus) or other Gram-positive infections. It is a semi-synthetic derivative of vancomycin. The FDA approved telavancin in September 2009 for complicated skin and skin structure infections... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 22, 2013 Category: Consumer Health News Tags: MRSA / Drug Resistance Source Type: news
FDA OKs Telavancin for Patients With Bacterial PneumoniaFDA OKs Telavancin for Patients With Bacterial Pneumonia
The US Food and Drug Administration approved the antibiotic telavancin to treat patients with hospital-acquired and ventilator-assisted bacterial pneumonia. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2013 Category: Consumer Health News Tags: Critical Care News Alert Source Type: news
FDA approves Theravance's lung drug for wider use
(Reuters) - The U.S. Food and Drug Administration approved Theravance Inc's antibiotic lung drug to treat a type of bacterial pneumonia affecting hospitalized patients, particularly those on ventilators. (Source: Reuters: Health)
Source: Reuters: Health - June 21, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
FDA approves Vibativ for hospitalized patients with bacterial pneumonia
The U.S. Food and Drug Administration today expanded the approved use of the antibiotic Vibativ (telavancin) to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by Staphylococcus aureus. Vibativ should be used for the treatment of HABP/VABP only when alternative treatments are not suitable. (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 21, 2013 Category: American Health Source Type: news
Protection Against Post-Influenza Bacterial Superinfection Offered By Interleukin-22
Researchers from the Pasteur Institute, Lille, France have shown in a mouse model that interleukin-22 protects against bacterial superinfections that can arise following influenza. Their research is published in the June 2013 issue of the Journal of Virology. Influenza A viral infection can lead to primary pneumonia and, later on, to serious complications including secondary bacterial pneumonia and sepsis. Post-influenza bacterial superinfections that occur during seasonal epidemics and pandemics are of great concern to human health and impose a considerable socio-economic burden... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 3, 2013 Category: Consumer Health News Tags: Flu / Cold / SARS Source Type: news
'Mystery illness' in Alabama a mix of flu, cold and pneumonia
MONTGOMERY, Ala., May 25 (UPI) -- Alabama officials say the "mystery illness" that hospitalized seven and killed two was influenza A, the virus associated with the cold and bacterial pneumonia. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 25, 2013 Category: Consumer Health News Source Type: news
Cause of Respiratory Disease Cluster in Alabama DeterminedCause of Respiratory Disease Cluster in Alabama Determined
A recent cluster of respiratory illnesses in Alabama was caused by a combination of influenza A, rhinovirus, and bacterial pneumonia. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
What Causes Spontaneous Pneumothorax?
Discussion
“A pneumothorax is a collection of air in the pleural space, and it can be categorized into spontaneous, traumatic or iatrogenic. Spontaneous pneumothorax can be further classified into primary with no clinical evidence of underlying lung disease or secondary due to pre-existing lung disease.”
Spontaneous pneumothorax is a condition that is relatively rare in pediatrics. There is a bimodal age distribution – neonates and late adolescence. It is caused by tearing of the visceral pleural. Clinical signs include chest pain, dyspnea, tachycardia, tracheal deviation towards contralateral side, hypo...
Source: PediatricEducation.org - May 20, 2013 Category: Pediatrics Authors: Donna M. D'Alessandro, M.D. Tags: Uncategorized Source Type: news
FDA Grants Fast Track Designation For Cubist's Late-Stage Antibiotic Candidate
Cubist Pharmaceuticals, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product (QIDP) indications, Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI). (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - May 7, 2013 Category: Pharmaceuticals Source Type: news
South Africa: Stop Smoking to Reduce Risk of Pneumonia in HIV+
[Health-e]HIV-positive smokers are at high risk of contracting bacterial pneumonia - a common and serious lung infection in people living with HIV - compared to their non-smoking counterparts. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - April 26, 2013 Category: Infectious Diseases Source Type: news
What Causes Spontaneous Pneumothorax?
Discussion
“A pneumothorax is a collection of air in the pleural space, and it can be categorized into spontaneous, traumatic or iatrogenic. Spontaneous pneumothorax can be further classified into primary with no clinical evidence of underlying lung disease or secondary due to pre-existing lung disease.”
Spontaneous pneumothorax is a condition that is relatively rare in pediatrics. There is a bimodal age distribution – neonates and late adolescence. It is caused by tearing of the visceral pleural. Clinical signs include chest pain, dyspnea, tachycardia, tracheal deviation towards contralateral side, hypo...
Source: PediatricEducation.org - April 22, 2013 Category: Pediatrics Authors: Donna M. D'Alessandro, M.D. Tags: Uncategorized Source Type: news
Can Respiratory Tract Cultures Predict VAP?
Ventilator-associated pneumonia (VAP) is an important complication in intensive care unit (ICU) patients. Current guidelines in the United States strongly recommend that surveillance be conducted for bacterial pneumonia in ICU patients, but diagnostic criteria have been criticized for the lack of sensitivity and specificity, especially regarding multidrug-resistant (MDR) pathogens. Brusselaers and investigators from Ghent University in Belgium performed a systematic review and meta-analysis to determine the sensitivity and specificity of surveillance cultures in predicting pathogens in VAP. Their results were published in ...
Source: SCCM RSS News - March 22, 2013 Category: Intensive Care Source Type: news
FDA Grants QIDP And Fast Track Designations For Cubist's Late-Stage Antibiotic Candidates
Cubist Pharmaceuticals, Inc.recently announced that the U.S. Food and Drug Administration (FDA) has designated the company’s late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI). (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 28, 2013 Category: Pharmaceuticals Source Type: news
